Mallinckrodt Completes Acquisition of Ocera Therapeutics and OCR-002, Its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy

STAINES-UPON-THAMES, United Kingdom, Dec. 11, 2017 -- (Healthcare Sales & Marketing Network) -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has closed the acquisition of Ocera Therapeutics, a clinica... Biopharmaceuticals, Mergers & Acquisitions Mallinckrodt, Ocera Therapeutics, hepatic encephalopathy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news